内科理论与实践

内科理论与实践 >

2022 , Vol. 17 >Issue 05: 405 - 407

DOI: https://doi.org/10.16138/j.1673-6087.2022.05.012

综述

老年肌少症合并心功能不全的研究进展

展开
  • a.全科医学科,上海交通大学医学院附属瑞金医院,上海 200025
    b.老年病科,上海交通大学医学院附属瑞金医院,上海 200025

收稿日期: 2021-07-28

  网络出版日期: 2022-11-04

收起

Research progress of senile sarcopenia with cardiac insufficiency

Expand

Received date: 2021-07-28

  Online published: 2022-11-04

Fold

本文引用格式

胡洁玲, 刘童君, 梁伟 . 老年肌少症合并心功能不全的研究进展[J]. 内科理论与实践, 2022 , 17(05) : 405 -407 . DOI: 10.16138/j.1673-6087.2022.05.012

参考文献

[1] Rosenberg IH. Sarcopenia: origins and clinical relevance[J]. J Nutr, 1997, 127(5 Suppl): 990S-991S.
[2] 姜珊, 康琳, 刘晓红. 2019亚洲肌少症诊断及治疗共识解读[J]. 中华老年医学杂志, 2020, 39(4): 373-376.
[3] Cruz-Jentoft AJ, Landi F, Topinková E, et al. Understanding sarcopenia as a geriatric syndrome[J]. Curr Opin Clin Nutr Metab Care, 2010, 13(1): 1-7.
[4] 俞锋, 贾敏江. 心功能不全诊治的新进展[J]. 心脏杂志, 2000, 12(1): 34-37.
[5] 黄峻. 盘点2016年心力衰竭临床研究进展[J]. 中华心力衰竭和心肌病杂志(中英文), 2017, 1(1): 42-47.
[6] 贾新菊. 射血分数正常的心力衰竭患者研究[J]. 心血管病防治知识, 2019, 9(15): 37-39.
[7] von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact[J]. J Cachexia Sarcopenia Muscle, 2010, 1(2): 129-133.
[8] von Haehling S. The wasting continuum in heart failure: from sarcopenia to cachexia[J]. Proc Nutr Soc, 2015, 74(4): 367-377.
[9] 吴琳瑾, 李静欣. 中国社区老年人肌少症患病率的Meta分析[J]. 现代预防医学, 2019, 46(22): 4109-4112.
[10] 刘嘉璐, 蔡雨阳. 上海市社区老年人肌少症的调查结果以及特点研究[J]. 健康大视野, 2019, 18: 248-249.
[11] Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF)[J]. Eur Heart J, 2013, 34(7): 512-519.
[12] 蒋庆庆, 戴朝晖, 段娟, 等. 老年患者肌少症与慢性心力衰竭相关性的临床研究[J]. 中华老年医学杂志, 2020, 39(2): 147-150.
[13] 信栓力, 焦凤辉, 常超, 等. 肌少症对老年慢性心力衰竭患者骨骼肌及心功能的影响[J]. 中华全科医师杂志, 2019, 18(8): 751-755.
[14] 肖潇, 胡松, 赵婷, 等. 肌少症对老年慢性心力衰竭患者肌力和活动能力的影响[J]. 中华全科医师杂志, 2019, 18(4): 343-346.
[15] 胡正光, 赵雯娟, 曹晓霞, 等. 肌少症对老年射血分数保留心力衰竭患者中期预后影响的研究[J]. 中国心血管杂志, 2020, 25(6): 547-550.
[16] Tsuchida K, Fujihara Y, Hiroki J, et al. Significance of sarcopenia evaluation in acute decompensated heart failure[J]. Int Heart J, 2018, 59(1): 143-148.
[17] Onoue Y, Izumiya Y, Hanatani S, et al. A simple sarcopenia screening test predicts future adverse events in patients with heart failure[J]. Int J Cardiol, 2016, 215: 301-306.
[18] Iwakami N, Nagai T, Furukawa TA, et al. Prognostic value of malnutrition assessed by controlling nutritional status score for long-term mortality in patients with acute heart failure[J]. Int J Cardiol, 2017, 230: 529-536.
[19] Can B, Kara O, Kizilarslanoglu MC, et al. Serum markers of inflammation and oxidative stress in sarcopenia[J]. Aging Clin Exp Res, 2017, 29(4): 745-752.
[20] Saitoh M, Dos Santos MR, Emami A, et al. Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure(SICA-HF)[J]. ESC Heart Fail, 2017, 4(4): 448-457.
[21] Wong A, Frishman W. Sarcopenia and cardiac dysfunction[J]. Cardiol Rev, 2020, 28(4): 197-202.
[22] Morley JE. Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia[J]. J Cachexia Sarcopenia Muscle, 2017, 8(4): 523-526.
[23] Bano G, Trevisan C, Carraro S, et al. Inflammation and sarcopenia: a systematic review and meta-analysis[J]. Maturitas, 2017, 96: 10-15.
[24] Fonseca GWPD, Santos MRD, Souza FR, et al. Sympatho-vagal imbalance is associated with sarcopenia in male patients with heart failure[J]. Arq Bras Cardiol, 2019, 112(6): 739-746.
[25] Bielecka-Dabrowa A, Ebner N, Dos Santos MR, et al. Cachexia, muscle wasting, and frailty in cardiovascular disease[J]. Eur J Heart Fail, 2020, 22(12): 2314-2326.
[26] Springer J, Springer JI, Anker SD. Muscle wasting and sarcopenia in heart failure and beyond[J]. ESC Heart Fail, 2017, 4(4): 492-498.
[27] Tanaka K, Valero-Muñoz M, Wilson RM, et al. Follistatin like 1 regulates hypertrophy in heart failure with preserved ejection fraction[J]. JACC Basic Transl Sci, 2016, 1(4): 207-221.
[28] Sundaresan NR, Bindu S, Pillai VB, et al. SIRT3 blocks aging-associated tissue fibrosis in mice by deacetylating and activating glycogen synthase kinase 3β[J]. Mol Cell Biol, 2015, 36(5): 678-692.
[29] 张音, 沈宏华, 许轶明, 等. 肌少症的诊断与治疗研究进展[J]. 内科理论与实践, 2021, 16(3): 220-224.
[30] Calvani R, Marini F, Cesari M, et al. Systemic inflammation, body composition, and physical performance in old community-dwellers[J]. J Cachexia Sarcopenia Muscle, 2017, 8(1): 69-77.
[31] Webster JM, Kempen LJAP, Hardy RS, et al. Inflammation and skeletal muscle wasting during cachexia[J]. Front Physiol, 2020, 11: 597675.
[32] Dirks AJ, Leeuwenburgh C. Tumor necrosis factor alpha signaling in skeletal muscle[J]. J Nutr Biochem, 2006, 17(8): 501-508.
[33] Oshima Y, Ouchi N, Sato K, et al. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart[J]. Circulation, 2008, 117(24): 3099-3108.
[34] Mattiotti A, Prakash S, Barnett P, et al. Follistatin-like 1 in development and human diseases[J]. Cell Mol Life Sci, 2018, 75(13): 2339-2354.
[35] Tsuda M, Fukushima A, Matsumoto J, et al. Protein acetylation in skeletal muscle mitochondria is involved in impaired fatty acid oxidation and exercise intolerance in heart failure[J]. J Cachexia Sarcopenia Muscle, 2018, 9(5): 844-859.
[36] Zhang J, Xiang H, Liu J, et al. Mitochondrial sirtuin 3: new emerging biological function and therapeutic target[J]. Theranostics, 2020, 10(18): 8315-8342.
[37] Parodi-Rullán RM, Chapa-Dubocq XR, Javadov S. Acetylation of mitochondrial proteins in the heart[J]. Front Physiol, 2018, 9: 1094.
[38] St-Jean-Pelletier F, Pion CH, Leduc-Gaudet JP, et al. The impact of ageing, physical activity, and pre-frailty on skeletal muscle phenotype, mitochondrial content, and intramyocellular lipids in men[J]. J Cachexia Sarcopenia Muscle, 2017, 8(2): 213-228.
[39] Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities[J]. J Endocrinol, 2016, 229(2): R67-R81.
[40] Hong SH, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences[J]. Int J Mol Sci, 2020, 21(2): 494.
Options
文章导航

/

〈 〉